Correlation Between Structure Therapeutics and Champions Oncology
Can any of the company-specific risk be diversified away by investing in both Structure Therapeutics and Champions Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Structure Therapeutics and Champions Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Structure Therapeutics American and Champions Oncology, you can compare the effects of market volatilities on Structure Therapeutics and Champions Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Structure Therapeutics with a short position of Champions Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Structure Therapeutics and Champions Oncology.
Diversification Opportunities for Structure Therapeutics and Champions Oncology
0.25 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Structure and Champions is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Structure Therapeutics America and Champions Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Champions Oncology and Structure Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Structure Therapeutics American are associated (or correlated) with Champions Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Champions Oncology has no effect on the direction of Structure Therapeutics i.e., Structure Therapeutics and Champions Oncology go up and down completely randomly.
Pair Corralation between Structure Therapeutics and Champions Oncology
Given the investment horizon of 90 days Structure Therapeutics American is expected to under-perform the Champions Oncology. In addition to that, Structure Therapeutics is 1.47 times more volatile than Champions Oncology. It trades about -0.08 of its total potential returns per unit of risk. Champions Oncology is currently generating about 0.11 per unit of volatility. If you would invest 426.00 in Champions Oncology on August 25, 2024 and sell it today you would earn a total of 29.00 from holding Champions Oncology or generate 6.81% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Structure Therapeutics America vs. Champions Oncology
Performance |
| Timeline |
| Structure Therapeutics |
| Champions Oncology |
Structure Therapeutics and Champions Oncology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Structure Therapeutics and Champions Oncology
The main advantage of trading using opposite Structure Therapeutics and Champions Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Structure Therapeutics position performs unexpectedly, Champions Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will offset losses from the drop in Champions Oncology's long position.| Structure Therapeutics vs. Day One Biopharmaceuticals | Structure Therapeutics vs. X4 Pharmaceuticals | Structure Therapeutics vs. Inozyme Pharma | Structure Therapeutics vs. Acumen Pharmaceuticals |
| Champions Oncology vs. Molecular Partners AG | Champions Oncology vs. MediciNova | Champions Oncology vs. Anebulo Pharmaceuticals | Champions Oncology vs. Shattuck Labs |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Complementary Tools
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |